We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aesica, University of Nottingham to develop novel amide chemical synthesis technique

Aesica, University of Nottingham to develop novel amide chemical synthesis technique

May 8, 2013
CenterWatch Staff

Aesica, a global contract manufacturing organization, has formed a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis.

This latest partnership is the Aesica Innovation Board’s (AIB) fourth with an academic institution in less than six months. AIB was established to help bridge the growing R&D gap by identifying early stage technologies for development into commercial applications.

Amide bond formation is fundamental in pharmaceutical manufacturing. A recent survey conducted by the Green Chemistry Institute Roundtable identified that amide bond formation was utilized in 84 % of a set of drug candidates. The partnership’s aim is to revolutionize traditional amide formation techniques by generating alternative methods for amide bond formation, which will be more eco-friendly and chemically versatile.

This innovative approach will be commercially available to Aesica customers in the next two to three months and already the company is actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology. Aesica envisages this new development helping pharmaceutical companies encountering problems with amide synthesis, and due to the utilization of more sustainable reagents, production costs will be lowered, while offering the potential of higher chemical yields.

The University of Nottingham has a strong track record of world-leading research in Green and Sustainable Chemistry. This collaboration builds upon recently announced plans to establish a Center of Excellence for Sustainable Chemistry, part-funded by an investment from the Higher Education Funding Council for England (HEFCE) U.K. Research Partnership Investment Fund. The center aims to form creative partnerships with innovative companies like Aesica to develop new chemical based technologies that minimise environmental impact and are both energy and resource efficient.

The University was confident about the success of this technology on a small-scale basis and was keen to test its robustness in a commercial application. Preliminary studies were undertaken using funds awarded by the Engineering and Physical Sciences Research Council (EPSRC) under the Research Development (Pathways to Impact) Funding Scheme. 

“Since realizing the initial use of our coupling agent in 2005, one of our goals has been to see this novel technology used in larger scale industrial environments,” said Simon Woodward, professor of synthetic organic chemistry, University of Nottingham. “We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture.”

Barrie Rhodes, director of technology development, Aesica, added, “This new amide production technology is hugely exciting, and ultimately, this will enable cheaper and simpler routes to market for many compounds. Professor Woodward's ability to carry out high calibre research coupled with our desire to bring new economically important and innovative technologies to the market is the basis for a truly collaborative partnership.”

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing